tyrosine kinase inhibitors Archives

Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases

Vanda Salutari

Article Type

Editorial

Published

24 Jun 2025

This editorial introduces the special series in Drugs in Context that explores treatment advancements for endometrial cancer through clinical case studies.

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors

Darren MC Poon, Kuen Chan, Angus Kwong-Chuen Leung, Brian Ng, Foon-Yiu Cheung, Steven Wai-Kwan Siu, Hong Kong Society of Uro-Oncology

Article Type

Original Research

Published

21 Jun 2023

In this study, the authors investigated the toxicity and efficacy of cabozantinib in Chinese patients who progressed on VEGFR TKIs and/or ICIs in real-life clinical practice.

Non-small-cell lung cancer: how to manage RET-positive disease

Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti, Giulio Metro, Giuseppe Lamberti

Article Type

Review

Published

11 Jul 2022

This article reviews the biology, clinicopathological characteristics, targeted therapies and mechanisms of resistance of advanced non-small-cell lung cancer harbouring RET fusions to provide treatment guidance for these patients.

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications

Matteo Santoni MD, Francesco Massari MD, Vincenzo Di Nunno MD, Alessandro Conti MD, Alessia Cimadamore MD, Marina Scarpelli MD, Rodolfo Montironi PhD, Liang Cheng PhD, Nicola Battelli MD, Antonio Lopez-Beltran PhD

Article Type

Editorial

Published

05 Jun 2018

This editorial describes the results of the most recent clinical trials on the use of immunotherapies in renal cell carcinoma and research for reliable biomarkers of tumour response in this setting, as well as the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies.